Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03975413 · ClinicalTrials.gov registry record
Fecal Microbiota Transplantation (FMT) in Multiple Sclerosis
A clinical trial, sponsored by Rush University Medical Center.
- Completed
- Registry status
- 1
- Enrollment target
NCT03975413: Completed study, sponsored by Rush University Medical Center.
NCT03975413 is a clinical trial that has completed, run by Rush University Medical Center. The registered enrollment target is 1 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03975413 has completed, sponsored by Rush University Medical Center.
- COMPLETED
- Registry status
- 1 participants
- Enrollment target
Study Summary
Multiple sclerosis (MS) is a chronic immune central nervous system (CNS) disease of unknown cause. Recent studies suggest that gut microbiota could be a trigger for the neuro-inflammation in MS and abnormal gut microbiota composition has been reported in MS patients. These data provided scientific rationale for microbiota-directed intervention, like stool transplant, for the treatment of MS.
Primary Outcome
Shotgun Metagenomics
Interventions
- OTHER Fecal Microbiota Transplantation (FMT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2018-09-25 |
| Est. Completion | 2020-05-01 |
What the finished NCT03975413 record still lists
NCT03975413 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 1 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Fecal Microbiota Transplantation (FMT) is the first listed.
NCT03975413 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03975413 about?
NCT03975413 is a clinical study titled "Fecal Microbiota Transplantation (FMT) in Multiple Sclerosis". Multiple sclerosis (MS) is a chronic immune central nervous system (CNS) disease of unknown cause. Recent studies suggest that gut microbiota could be a trigger for the neuro-inflammation in MS and abnormal gut microbiota composition has been reported in MS patients. These data provided scientific r...
What is the current status of trial NCT03975413?
This trial is currently completed. The enrollment target is 1 participants. The study started on 2018-09-25. Estimated completion is 2020-05-01.
What interventions are being tested in trial NCT03975413?
The interventions under investigation include: Fecal Microbiota Transplantation (FMT) (OTHER).
Who is sponsoring clinical trial NCT03975413?
This trial is sponsored by Rush University Medical Center, which has 320 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI